Tuberculosis drug resistance mutation database A Sandgren, M Strong, P Muthukrishnan, BK Weiner, GM Church, ... PLoS medicine 6 (2), e1000002, 2009 | 659 | 2009 |
The Mycobacterium tuberculosis regulatory network and hypoxia JE Galagan, K Minch, M Peterson, A Lyubetskaya, E Azizi, L Sweet, ... Nature 499 (7457), 178-183, 2013 | 469 | 2013 |
Interpreting Expression Data with Metabolic Flux Models: Predicting Mycobacterium tuberculosis Mycolic Acid Production C Colijn, A Brandes, J Zucker, DS Lun, B Weiner, MR Farhat, TY Cheng, ... PLoS computational biology 5 (8), e1000489, 2009 | 464 | 2009 |
TB database: an integrated platform for tuberculosis research TBK Reddy, R Riley, F Wymore, P Montgomery, D DeCaprio, R Engels, ... Nucleic acids research 37 (suppl_1), D499-D508, 2009 | 284 | 2009 |
HOXA10 controls osteoblastogenesis by directly activating bone regulatory and phenotypic genes MQ Hassan, R Tare, SH Lee, M Mandeville, B Weiner, M Montecino, ... Molecular and cellular biology 27 (9), 3337-3352, 2007 | 195 | 2007 |
TB database 2010: overview and update JE Galagan, P Sisk, C Stolte, B Weiner, M Koehrsen, F Wymore, ... Tuberculosis 90 (4), 225-235, 2010 | 142 | 2010 |
Comparative analysis of mycobacterium and related actinomycetes yields insight into the evolution of mycobacterium tuberculosis pathogenesis AM McGuire, B Weiner, ST Park, I Wapinski, S Raman, G Dolganov, ... BMC genomics 13, 1-27, 2012 | 112 | 2012 |
Pridopidine activates neuroprotective pathways impaired in Huntington Disease M Geva, R Kusko, H Soares, KD Fowler, T Birnberg, S Barash, ... Human molecular genetics 25 (18), 3975-3987, 2016 | 105 | 2016 |
SWI/SNF chromatin remodeling complex is obligatory for BMP2‐induced, Runx2‐dependent skeletal gene expression that controls osteoblast differentiation DW Young, J Pratap, A Javed, B Weiner, Y Ohkawa, A Van Wijnen, ... Journal of cellular biochemistry 94 (4), 720-730, 2005 | 104 | 2005 |
A blind deconvolution approach to high-resolution mapping of transcription factor binding sites from ChIP-seq data DS Lun, A Sherrid, B Weiner, DR Sherman, JE Galagan Genome biology 10, 1-12, 2009 | 85 | 2009 |
Genome sequencing and analysis of geographically diverse clinical isolates of herpes simplex virus 2 RM Newman, SL Lamers, B Weiner, SC Ray, RC Colgrove, F Diaz, L Jing, ... Journal of virology 89 (16), 8219-8232, 2015 | 74 | 2015 |
Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants RM Newman, T Kuntzen, B Weiner, A Berical, P Charlebois, C Kuiken, ... The Journal of infectious diseases 208 (1), 17-31, 2013 | 54 | 2013 |
Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy JZ Li, B Chapman, P Charlebois, O Hofmann, B Weiner, AJ Porter, ... PLoS One 9 (3), e90485, 2014 | 46 | 2014 |
Independent Large Scale Duplications in Multiple M. tuberculosis Lineages Overlapping the Same Genomic Region B Weiner, J Gomez, TC Victor, RM Warren, A Sloutsky, BB Plikaytis, ... PLoS One 7 (2), e26038, 2012 | 38 | 2012 |
Inferring carbon sources from gene expression profiles using metabolic flux models A Brandes, DS Lun, K Ip, J Zucker, C Colijn, B Weiner, JE Galagan PLoS One 7 (5), e36947, 2012 | 34 | 2012 |
A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis CJ Ross, F Towfic, J Shankar, D Laifenfeld, M Thoma, M Davis, B Weiner, ... Genome medicine 9, 1-15, 2017 | 33 | 2017 |
Intervention strategies for microbial therapeutics in cancer immunotherapy V Gopalakrishnan, B Weiner, CB Ford, BR Sellman, SA Hammond, ... Immuno-Oncology Technology 6, 9-17, 2020 | 12 | 2020 |
Similarities and differences in properties of glatiramer acetate (Copaxone (R), Teva) versus polimunol (Synthon) using standard and emerging technologies A Komlosh, T Hasson, K Wells-Knecht, T Wells-Knecht, R Krispin, G Papir, ... EUROPEAN JOURNAL OF NEUROLOGY 23, 199-199, 2016 | 5 | 2016 |
607 MCGRAW trial: evaluation of the safety and efficacy of an oral microbiome intervention (SER-401) in combination with nivolumab in first line metastatic melanoma patients IG Oliva, O Hamid, P Ott, G Boland, R Sullivan, K Grossmann, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 4 | 2022 |
Comparison of physicochemical, biological and genomic characteristics of differently manufactured glatiramoids to ensure MS patient safety A Komlosh, T Hasson, K Wells-Knecht, T Molotsky, R Krispin, G Papir, ... Multiple Sclerosis Journal 21, 687-688, 2015 | 3 | 2015 |